alpha-aminopyridine has been researched along with ivosidenib in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 11 (78.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sweet, K; Talati, C | 1 |
| Tiong, IS; Wei, AH | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| DiNardo, CD; Wei, AH | 1 |
| Beaver, JA; Charlab, R; de Claro, RA; Deisseroth, A; Dorff, SE; Farrell, AT; Kazandjian, D; Mulkey, F; Norsworthy, KJ; Pazdur, R; Przepiorka, D; Scott, EC; Sridhara, R; Ward, AF | 1 |
| Zeidner, JF | 1 |
| Cardinali, V; Cerchione, C; Falini, B; Martelli, MP; Martinelli, G; Martino, G | 1 |
| Cerchione, C; Martinelli, G | 1 |
| Almon, C; Choe, S; Cooper, M; DiNardo, CD; Döhner, H; Fan, B; Fathi, AT; Franovic, A; Frattini, MG; Hua, L; Kantarjian, HM; Lersch, F; Löwenberg, B; McCloskey, JK; Mims, AS; Nabhan, S; Odenike, O; Ossenkoppele, GJ; Patel, PA; Pollyea, DA; Pratz, KW; Roshal, M; Savona, MR; Seet, CS; Stein, AS; Stein, EM; Stone, RM; Tallman, MS; Wang, H; Winer, ES; Wu, B | 1 |
| Baran, N; Bellvert, F; Boet, E; Bories, P; Bosc, C; Broin, N; Carroll, M; Cassan, C; Castellano, R; Castelli, FA; Cazals, G; Chu-Van, E; Cissé, MY; Cognet, G; Collette, Y; Conti, M; DiNardo, CD; Farge, T; Fenaille, F; Fernando, L; Gales, L; Gibon, Y; Gotanègre, M; Hosseini, M; Hucteau, A; Jourdan, F; Kaoma, T; Konopleva, M; Larrue, C; Le Cam, L; Linares, LK; Loric, S; Marszalek, JR; Montersino, C; Mouchel, PL; Nicolay, B; Pancaldi, V; Portais, JC; Poupin, N; Récher, C; Ronseaux, S; Sabatier, M; Sahal, A; Saland, E; Sarry, JE; Selak, MA; Stuani, L; Takahashi, K; Turtoi, A; Turtoi, E; Vey, N; Wang, F; Zavoriti, A | 1 |
| Andrew Futreal, P; Bhalla, KN; DiNardo, CD; Frattini, M; Furudate, K; Garcia-Manero, G; Gumbs, C; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, M; Little, LD; Liu, G; MacBeth, KJ; Matthews, JA; Morita, K; Patel, KP; Ravandi, F; Song, X; Takahashi, K; Tanaka, T; Thompson, EJ; Wang, F; Wu, B; Yan, Y; Zhang, J | 1 |
| de Botton, S; Dragani, M | 1 |
| Thol, F | 1 |
| Almon, C; Chen, Y; Cooper, M; Fan, B; Hossain, M; Hua, L; Nabhan, S; Yang, H; Yin, F | 1 |
5 review(s) available for alpha-aminopyridine and ivosidenib
| Article | Year |
|---|---|
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Cytarabine; Daunorubicin; Female; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Pyridines; Staurosporine; Triazines | 2018 |
New drugs creating new challenges in acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Pyrazines; Pyridines; Staurosporine; Triazines; United States; United States Food and Drug Administration | 2019 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Enasidenib and ivosidenib in AML.
Topics: Aminopyridines; Antineoplastic Agents; Cell Differentiation; Clinical Trials as Topic; Glutarates; Glycine; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; Leukemia, Myeloid, Acute; Multicenter Studies as Topic; Mutation, Missense; NADP; Pyridines; Syndrome; Triazines | 2020 |
SOHO State of the Art Updates and Next Questions: IDH Inhibition.
Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Middle Aged; Pyridines; Triazines | 2021 |
2 trial(s) available for alpha-aminopyridine and ivosidenib
| Article | Year |
|---|---|
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Agents; Female; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Pyridines; Treatment Outcome; Triazines; Young Adult | 2021 |
Pharmacokinetic/Pharmacodynamic Evaluation of Ivosidenib or Enasidenib Combined With Intensive Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed IDH1/2-Mutant Acute Myeloid Leukemia.
Topics: Adult; Aminopyridines; Antineoplastic Agents; Consolidation Chemotherapy; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines | 2022 |
7 other study(ies) available for alpha-aminopyridine and ivosidenib
| Article | Year |
|---|---|
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
Topics: Aminopyridines; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration | 2020 |
Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
Topics: Aminopyridines; Cell Differentiation; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Pyridines; Triazines; United States; United States Food and Drug Administration | 2020 |
Acute leukemias in 2020: state of the art.
Topics: Acute Disease; Aminopyridines; Antineoplastic Agents; Antineoplastic Agents, Immunological; Congresses as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Leukemia; Pyridines; Recombinant Fusion Proteins; Staurosporine; Triazines | 2020 |
Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia.
Topics: Acute Disease; Aminopyridines; Animals; Cell Line, Tumor; Doxycycline; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Glycine; HL-60 Cells; Humans; Isocitrate Dehydrogenase; Isoenzymes; Leukemia, Myeloid; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitochondria; Mutation; Oxadiazoles; Oxidative Phosphorylation; Piperidines; Pyridines; Triazines; Xenograft Model Antitumor Assays | 2021 |
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Topics: Aged; Aminopyridines; Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Core Binding Factor Alpha 2 Subunit; Dioxygenases; DNA Methylation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenomics; Evolution, Molecular; Female; Glycine; High-Throughput Nucleotide Sequencing; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Middle Aged; Multigene Family; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Pyridines; ras Proteins; Repressor Proteins; RNA-Seq; Signal Transduction; Single-Cell Analysis; Stem Cells; Triazines | 2021 |
What to use to treat AML: the role of emerging therapies.
Topics: Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Cytarabine; Daunorubicin; Drug Approval; Drug Discovery; Glycine; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Triazines | 2021 |